Chiusura precedente | 0,0500 |
Aperto | 0,0500 |
Denaro | 0,0000 |
Lettera | 0,0500 |
Prezzo d'esercizio | 2,50 |
Scadenza | 2024-07-19 |
Min-Max giorno | 0,0500 - 0,0500 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 202 |
The engagement is an additional step in the Company's path towards marketing clearance with the FDABRAINTREE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, announced today its partnership with a Contract Research Organization (CRO) in the U.S. This is an additional step in the preparations to the commencement of the Company's planned upcoming clinical trial.
The presentation follows successful extensive uses of the Company’s endovascular robotic system in pre-clinical studiesBRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023. The abstract is to be present
The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials followed by regulatory approval and commercializationBRAINTREE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, announces another step in its commitment to advance the commercialization processes of LIBERTY® with th